Five versus more than five years of tamoxifib for lymph node-nagative breast cancer: Updated findings from the national surgical adjuvant breast and bowel project B-14 Randomized trial

Journal of the National Cancer Institute

Volumn 93, Issue 9, 2001, Pages 684-690

  Fisher, Bernard ^a,f   Dignam, James ^b,c   Bryant, John ^d   Wolmark, Norman ^e  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e ALLEGHENY GENERAL HOSPITAL   (United States)

^f NSABP Foundation Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PLACEBO; TAMOXIFEN; ANTIESTROGEN;

ADULT; AGE; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST SURGERY; CANCER REGRESSION; CANCER RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LONG TERM CARE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MODEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; AGED; BREAST TUMOR; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; TIME;

ADULT; AGED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; TAMOXIFEN; TIME FACTORS;

EID: 0035795683     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.9.684     Document Type: Article

References (27)

1. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
2. Systemic therapy in node-negative patients: Updated findings from NSABP clinical trials
3. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
4. Five years of tamoxifen-or more?
5. Should adjuvant tamoxifen therapy be stopped at 5 years?
6. Limits on tamoxifen duration questioned
7. Experts review NCI recommendation to limit tamoxifen duration to five years
8. The optimal duration of adjuvant tamoxifen treatment for breast cancer remains uncertain: Randomize into aTTom
9. Long term adjuvant therapy for primary breast cancer
10. Preliminary results from the Cancer Research Campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer
11. Adjuvant tamoxifen: How long before we know how long?
12. More large trials needed to decide best duration of treatment with tamoxifen
13. The duration of adjuvant tamoxifen therapy
14. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer
15. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer
16. Tamoxifen: The long and short of it
17. Nonparametric estimation from incomplete observations
18. Evaluation of survival data and two new rank order statistics arising in its consideration
19. Regression models and life tables
20. Early stopping of a clinical trial when there is evidence of no treatment benefit: Protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project
21. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer
22. Tamoxifen adjuvant treatment duration in early breast cancer: Initial results of a randomized study comparing short-term treatment with long-term treatment
23. Tamoxifen for early breast cancer: An overview of the randomized trials
24. Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial